What is the recommended treatment for an acute relapse in a patient with progressive multiple sclerosis?

Treatment of Acute Relapse in Progressive MS

High-dose intravenous methylprednisolone (typically 1000 mg daily for 3-5 days) is the first-line treatment for acute relapses in progressive MS patients, with plasma exchange reserved as rescue therapy for severe relapses that fail to respond to corticosteroids. 1, 2, 3

First-Line Treatment: High-Dose Corticosteroids

The standard approach for treating acute relapses in progressive MS follows the same principles as relapsing-remitting MS:

• Intravenous methylprednisolone 1000 mg daily for 3-5 days is the established first-line therapy 4, 5
• Oral high-dose methylprednisolone is an acceptable alternative with equivalent efficacy 4
• Treatment should be initiated promptly once a true relapse is confirmed, as early intervention improves recovery speed 3, 6

Critical Distinction: True Relapse vs Pseudo-Relapse

Before initiating corticosteroids, you must confirm this is a genuine relapse and not a pseudo-relapse:

• True relapse: New focal inflammatory demyelination causing new neurological symptoms lasting >24 hours without fever or infection 2, 5
• Pseudo-relapse: Transient worsening of old symptoms due to systemic triggers (infection, fever, heat exposure, metabolic derangements, sleep deprivation) 1, 3

Do not treat pseudo-relapses with corticosteroids - instead, address the underlying trigger (treat infection, correct metabolic abnormalities, etc.) 3

Second-Line Treatment: Plasma Exchange

If severe neurological deficits persist after completing corticosteroid therapy:

• Plasma exchange (5-7 exchanges over 10-14 days) should be considered as rescue therapy 6, 4, 5
• This is particularly indicated when:
  • Severe functional impairment remains after steroids
  • Repeat MRI shows persistent contrast enhancement of the symptomatic lesion 6
  • The relapse is fulminant or tumefactive in nature 6

Evidence shows plasma exchange is efficacious in approximately 40-50% of patients with steroid-refractory relapses 4

Important Caveats for Progressive MS

While the acute relapse treatment is the same regardless of MS subtype, several considerations are specific to progressive MS patients:

Limited Long-Term Benefit in Progressive Forms

• Progressive MS patients (both primary and secondary progressive) may experience relapses, but the overall benefit from disease-modifying therapies is substantially lower compared to relapsing-remitting MS 7, 1
• In the absence of active inflammatory disease (no relapses or new MRI lesions), progressive MS patients derive minimal benefit from current therapies 1
• Historical data shows progression-free survival after AHSCT was only 33-57% in progressive MS versus 71-87% in relapsing-remitting MS 7

Treatment Algorithm for Progressive MS Relapse

1. Confirm true relapse (not pseudo-relapse from infection, fever, or other trigger)
2. Initiate IV methylprednisolone 1000 mg daily × 3-5 days immediately
3. Assess response at 2-4 weeks:
   • If good recovery → supportive care and rehabilitation
   • If severe deficits persist → obtain repeat MRI
4. If persistent enhancement on MRI and severe disability → proceed to plasma exchange (5-7 sessions)
5. Consider intensified rehabilitation regardless of pharmacologic response 4

Treatments to Avoid

• Single-dose natalizumab as acute relapse therapy has been studied and shown NOT to improve outcomes 6
• Vitamin D supplementation does not reduce relapse rates or severity 8
• Omega-3 fatty acid supplementation should not be used for relapse prevention 8

Monitoring and Follow-Up

After treating the acute relapse:

• Reassess neurological status at 4-6 weeks to document recovery
• Consider MRI at 3 months if clinical recovery is incomplete
• Evaluate whether the relapse indicates inadequate disease control requiring change in disease-modifying therapy
• Implement intensive rehabilitation to maximize functional recovery 4

The key principle is that treating acute relapses in progressive MS focuses on accelerating recovery from the current episode, but does not alter the underlying progressive disease trajectory unless there is concurrent active inflammatory disease 7, 1.